SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis

SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. ASH 2014.

Poster